Ben Libberton 2/10/25 Ben Libberton 2/10/25 Breakthrough in Parkinson's Treatment: Diabetes Drug Shows Promise Read More Ben Libberton 1/7/25 Ben Libberton 1/7/25 Unlocking the Potential of GLP-1 Receptor: A Revolutionary Approach to Therapy Read More Ben Libberton 12/2/24 Ben Libberton 12/2/24 Green Lab Certification: A Win for InSingulo and the Environment Read More Ben Libberton 10/28/24 Ben Libberton 10/28/24 Advancing Drug Discovery for GLP-1R: Addressing Complexities with Innovative Approaches Read More Ben Libberton 8/20/24 Ben Libberton 8/20/24 Fresh new team photos Read More Ben Libberton 10/4/23 Ben Libberton 10/4/23 Navigating the Complex Landscape of Drug Development: Strategies and Solutions Read More Ben Libberton 8/25/23 Ben Libberton 8/25/23 Real-Time Insights: How dISA Enables Equilibrium Monitoring Read More Ben Libberton 8/11/23 Ben Libberton 8/11/23 Membrane Proteins: Their time has come in drug discovery Read More Ben Libberton 7/11/23 Ben Libberton 7/11/23 Introducing Scott Kozak: InSingulo's First US Business Development Team Member Read More Ben Libberton 6/27/23 Ben Libberton 6/27/23 Unleashing the Potential of Membrane Protein Research with dISA Read More Ben Libberton 6/9/23 Ben Libberton 6/9/23 Unveiling the Success of our Attendance at the BIO International Convention Read More Ben Libberton 4/18/23 Ben Libberton 4/18/23 The perfect cell-free expression system for your membrane proteins Read More Ben Libberton 3/23/23 Ben Libberton 3/23/23 Building sales and marketing in 2023 Read More Ben Libberton 3/21/23 Ben Libberton 3/21/23 R&D Updates for InSingulo Read More Ben Libberton 3/13/23 Ben Libberton 3/13/23 2022 was a year of growth for InSingulo Read More Ben Libberton 3/10/23 Ben Libberton 3/10/23 Join us for workshops in Gothenburg Read More Ben Libberton 3/3/23 Ben Libberton 3/3/23 Green Lab Certification Read More Ben Libberton 1/11/23 Ben Libberton 1/11/23 Financing success Read More Ben Libberton 6/16/22 Ben Libberton 6/16/22 New Patent granted in the US An important step in IP strategy for InSingulo. Read More
Ben Libberton 2/10/25 Ben Libberton 2/10/25 Breakthrough in Parkinson's Treatment: Diabetes Drug Shows Promise Read More
Ben Libberton 1/7/25 Ben Libberton 1/7/25 Unlocking the Potential of GLP-1 Receptor: A Revolutionary Approach to Therapy Read More
Ben Libberton 12/2/24 Ben Libberton 12/2/24 Green Lab Certification: A Win for InSingulo and the Environment Read More
Ben Libberton 10/28/24 Ben Libberton 10/28/24 Advancing Drug Discovery for GLP-1R: Addressing Complexities with Innovative Approaches Read More
Ben Libberton 10/4/23 Ben Libberton 10/4/23 Navigating the Complex Landscape of Drug Development: Strategies and Solutions Read More
Ben Libberton 8/25/23 Ben Libberton 8/25/23 Real-Time Insights: How dISA Enables Equilibrium Monitoring Read More
Ben Libberton 8/11/23 Ben Libberton 8/11/23 Membrane Proteins: Their time has come in drug discovery Read More
Ben Libberton 7/11/23 Ben Libberton 7/11/23 Introducing Scott Kozak: InSingulo's First US Business Development Team Member Read More
Ben Libberton 6/27/23 Ben Libberton 6/27/23 Unleashing the Potential of Membrane Protein Research with dISA Read More
Ben Libberton 6/9/23 Ben Libberton 6/9/23 Unveiling the Success of our Attendance at the BIO International Convention Read More
Ben Libberton 4/18/23 Ben Libberton 4/18/23 The perfect cell-free expression system for your membrane proteins Read More
Ben Libberton 6/16/22 Ben Libberton 6/16/22 New Patent granted in the US An important step in IP strategy for InSingulo. Read More
